Literature DB >> 24474579

Image guided surgery for the resection of brain tumours.

Damiano Giuseppe Barone1, Theresa A Lawrie, Michael G Hart.   

Abstract

BACKGROUND: Extent of resection is believed to be a key prognostic factor in neuro-oncology. Image guided surgery uses a variety of tools or technologies to help achieve this goal. It is not clear whether any of these, sometimes very expensive, tools (or their combination) should be recommended as part of standard care for patient with brain tumours. We set out to determine if image guided surgery offers any advantage in terms of extent of resection over surgery without any image guidance and if any one tool or technology was more effective.
OBJECTIVES: To compare image guided surgery with surgery either not using any image guidance or to compare surgery using two different forms of image guidance. The primary outcome criteria was extent of resection and adverse events. Other outcome criteria were overall survival; progression free survival; and quality of life (QoL). SEARCH
METHODS: The following databases were searched, the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2013), MEDLINE (1948 to March, week 10, 2013) and EMBASE (1970 to 2013, week 10). Reference lists of all identified studies were searched. Two journals, the Journal of Neuro-Oncology and Neuro-oncology, were handsearched from 1991 to 2013, including all conference abstracts. Neuro-oncologists, trial authors and manufacturers were contacted regarding ongoing and unpublished trials. SELECTION CRITERIA: Study participants included patients of all ages with a presumed new or recurrent brain tumour (any location or histology) from clinical examination and imaging (computed tomography (CT), magnetic resonance imaging (MRI) or both). Image guidance interventions included intra-operative MRI (iMRI); fluorescence guided surgery; neuronavigation including diffusion tensor imaging (DTI); and ultrasonography. Included studies had to be randomised controlled trials (RCTs) with comparisons made either with patients having surgery without the image guidance tool in question or with another type of image guidance tool. Subgroups were to include high grade glioma; low grade glioma; brain metastasis; skull base meningiomas; and sellar or parasellar tumours. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed the search results for relevance, undertook critical appraisal according to known guidelines, and extracted data using a pre-specified pro forma. MAIN
RESULTS: Four RCTs were identified, each using a different image guided technique: 1. iMRI (58 patients), 2. 5-aminolevulinic acid (5-ALA) fluorescence guided surgery (322 patients), 3. neuronavigation (45 patients) and 4. DTI-neuronavigation (238 patients). Meta-analysis was not appropriate due to differences in the tumours included (eloquent versus non-eloquent locations) and variations in the image guidance tools used in the control arms (usually selective utilisation of neuronavigation). There were significant concerns regarding risk of bias in all the included studies, especially for the study using DTI-neuronavigation. All studies included patients with high grade glioma, with one study also including patients with low grade glioma. The extent of resection was increased with iMRI (risk ratio (RR) (incomplete resection) 0.13, 95% CI 0.02 to 0.96, low quality evidence), 5-ALA (RR 0.55, 95% CI 0.42 to 0.71) and DTI-neuronavigation (RR 0.35, 95% CI 0.20 to 0.63, very low quality evidence). Insufficient data were available to evaluate the effects of neuronavigation on extent of resection. Reporting of adverse events was incomplete, with a suggestion of significant reporting bias. Overall, reported events were low in most studies, but there was concern that surgical resection using 5-ALA may lead to more frequent early neurological deficits. There was no clear evidence of improvement in overall survival (OS) with 5-ALA (hazard ratio (HR) 0.82, 95% CI 0.62 to 1.07) or DTI-neuronavigation (HR 0.57, 95% CI 0.32 to 1.00) in patients with high grade glioma. Progression-free survival (PFS) data were not available in the appropriate format for analysis.Data for quality of life (QoL) were only available for one study and suffered from significant attrition bias. AUTHORS'
CONCLUSIONS: There is low to very low quality evidence (according to GRADE criteria) that image guided surgery using iMRI, 5-ALA or DTI-neuronavigation increases the proportion of patients with high grade glioma that have a complete tumour resection on post-operative MRI. There is a theoretical concern that maximising the extent of resection may lead to more frequent adverse events but this was poorly reported in the included studies. Effects of image guided surgery on survival and QoL are unclear. Further research, including studies of ultrasound guided surgery, is needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24474579      PMCID: PMC6457761          DOI: 10.1002/14651858.CD009685.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  59 in total

1.  Comparison of Panitumumab-IRDye800CW and 5-Aminolevulinic Acid to Provide Optical Contrast in a Model of Glioblastoma Multiforme.

Authors:  Tiara S Napier; Neha Udayakumar; Aditi H Jani; Yolanda E Hartman; Hailey A Houson; Lindsay Moore; Hope M Amm; Nynke S van den Berg; Anna G Sorace; Jason M Warram
Journal:  Mol Cancer Ther       Date:  2020-06-30       Impact factor: 6.261

2.  Recurrent glioblastoma: who receives tumor specific treatment and how often?

Authors:  Rieke Steffens; Sabine Semrau; Godehard Lahmer; Florian Putz; Sebastian Lettmaier; Ilker Eyüpoglu; Michael Buchfelder; Rainer Fietkau
Journal:  J Neurooncol       Date:  2016-02-23       Impact factor: 4.130

3.  Intraoperative assistive technologies-the way ahead.

Authors:  Aliasgar V Moiyadi
Journal:  Neurosurg Rev       Date:  2015-04-12       Impact factor: 3.042

Review 4.  The evolution of cancer surgery and future perspectives.

Authors:  Lynda Wyld; Riccardo A Audisio; Graeme J Poston
Journal:  Nat Rev Clin Oncol       Date:  2014-11-11       Impact factor: 66.675

Review 5.  The role of surgery in grade II/III oligodendroglial tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  CNS Oncol       Date:  2015-10-19

6.  A Connectomic Atlas of the Human Cerebrum-Chapter 1: Introduction, Methods, and Significance.

Authors:  Cordell M Baker; Joshua D Burks; Robert G Briggs; Andrew K Conner; Chad A Glenn; Goksel Sali; Tressie M McCoy; James D Battiste; Daniel L O'Donoghue; Michael E Sughrue
Journal:  Oper Neurosurg (Hagerstown)       Date:  2018-12-01       Impact factor: 2.703

7.  Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy.

Authors:  Minbiao Ji; Spencer Lewis; Sandra Camelo-Piragua; Shakti H Ramkissoon; Matija Snuderl; Sriram Venneti; Amanda Fisher-Hubbard; Mia Garrard; Dan Fu; Anthony C Wang; Jason A Heth; Cormac O Maher; Nader Sanai; Timothy D Johnson; Christian W Freudiger; Oren Sagher; Xiaoliang Sunney Xie; Daniel A Orringer
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

8.  Determination of intra-axial brain tumors cellularity through the analysis of T2 Relaxation time of brain tumors before surgery using MATLAB software.

Authors:  Jamil Abdolmohammadi; Mohsen Shafiee; Fariborz Faeghi; Douman Arefan; Alireza Zali; Rouzbeh Motiei-Langroudi; Zahra Farshidfar; Ali Kiani Nazarlou; Ali Tavakkoli; Mohammad Yarham
Journal:  Electron Physician       Date:  2016-08-25

Review 9.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

10.  Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Authors:  Longhua Qiu; Feng Zhang; Yaoping Shi; Zhibin Bai; Jianfeng Wang; Yonggang Li; Donghoon Lee; Christopher Ingraham; Xiaoyuan Feng; Xiaoming Yang
Journal:  Radiology       Date:  2015-11-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.